Oxford Immunotec Schedules First Quarter 2020 Earnings Release and Conference Call for May 5, 2020

Udgivet den 29-04-2020  |  kl. 13:15  |  

OXFORD, United Kingdom and MARLBOROUGH, Mass., April 29, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the Company), a global, high-growth diagnostics company, today announced that it plans to release first quarter 2020 financial results before the open of the market on Tuesday, May 5, 2020.  Dr. Peter Wrighton-Smith, Chief Executive Officer, and Matt McLaughlin, Chief Financial Officer, will host a conference call to review the Company's financial results at 8:00 a.m. Eastern Time the same day.  The call will be concurrently webcast.

To listen to the conference call on your telephone, please dial (855) 363-5047 for United States callers or +1 (484) 365-2897 for international callers and reference confirmation code 8473556, approximately 15 minutes prior to start time.  To access the live audio webcast or subsequent archived recording, visit the Investor Relations section of Oxford Immunotec's website at www.oxfordimmunotec.com.  The replay will be available on the Company's website for approximately 60 days.

About Oxford Immunotec

Oxford Immunotec Global PLC is a global, high-growth diagnostics company.  We bring energy and invention to a world in need of diagnostic truth.  Our leading product, the T-SPOT®.TB test, is used for diagnosing infection with Tuberculosis, the world's largest cause of death from infectious disease.  The T-SPOT.TB test has been approved for sale in over 60 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China.  The Company is headquartered near Oxford, U.K. and in Marlborough, MA.  Additional information can be found at www.oxfordimmunotec.com.

T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd.

CONTACTS:

For Media and Investor Inquiries:
Matt McLaughlin
Chief Financial Officer
Oxford Immunotec
Tel: +1 (508) 573-9953
mtmclaughlin@oxfordimmunotec.com

\Hugin

Udgivet af: NPinvestordk

Mest læste lige nu

Tidlig julegave fra Danske Bank: Udbetaler udbytte fra salg i Norge
Novo/Sydbank: Ikke den store overraskelse at Zepbound giver større vægttab end Wegovy
Vestas får skåret over en tredjedel af kursmålet hos britiske HSBC
Aktier/åbning: Vestas stiger i morgensurt C25 trods negativ analyse
KORR: Vestas-direktør ser frem til afgørelse om dansk havvindudbud
 

Seneste nyheder

10:49 Dansk økonomi ventes at vokse med tre procent inden opbremsning
10:03 Danmark/DE: Regeringen ser større vækst men også øget usikkerhed
10:00 KORR: Vestas-direktør ser frem til afgørelse om dansk havvindudbud
09:53 Unicredit vil finpudse på opkøbstilbud på rivalen Banco frem til marts
09:22 Vestas-direktør ser frem til afgørelse om dansk havvindudbud
09:20 Aktier/åbning: Vestas får lidt revanche i ellers flad åbning
09:04 Sydbank: Svensk inflation holder sig inden for rammerne trods ny stigning
08:36 Obligationer/åbning: Små rentefald trods opløftende nyt fra den tyske industri
08:26 Bunden kan være nået: Tyske fabriksordrer overrasker med mindre dyk i oktober
08:08 Aktier/tendens: Vestas i fokus efter onsdagens kurstæsk i ventet afdæmpet start
07:46 Mærsks asiatiske konkurrenter er med en enkelt undtagelse alle i rødt
07:13 Råvarer: Oliepriserne finder fodfæste efter stort fald inden oliekartels møde
07:08 Obligationer/tendens: Tyske fabrikstal tager fokus inden åbning med små rentefald i vente
06:52 Vestas og GE Vernova fører an på amerikansk landvind-marked
06:42 Asien: Varsomme investorer skæver til Sydkorea efter uro
06:34 Storbank topper buddene for S&P 500 i 2025 og ser aktier stige 15 pct.
06:34 Novo/Guggenheim: Kursmål skåret med 10 pct.
06:34 Rockwool får skåret kursmålet til 2810 kr. fra 2990 kr. af JP Morgan
06:34 Greenmobility vil rejse 15 mio. kr. gennem rettet emission
06:34 Analytikere mener at studie af Eli Lillys og Novos vægttabsmidler bekræfte konsensus